- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Ira Klein on Pharmaceutical Interest in Alternative Payment Models
Pharmaceutical companies would like to see value-based contracts that are multi-year and over large populations, said Ira Klein, MD, MBA, FACP, senior director of healthcare quality strategy for the Strategic Customer Group at Janssen Pharmaceuticals.
Pharmaceutical companies would like to see value-based contracts that are multi-year and over large populations, said Ira Klein, MD, MBA, FACP, senior director of healthcare quality strategy for the Strategic Customer Group at Janssen Pharmaceuticals.
Transcript (slightly moified)
What are pharmaceutical companies interested in with respect to alternative payment models?
I think that anything that really helps in unlocking the true value of a product over time is what the pharmaceutical industry is interested in. Now, if you think about the research and development time cycle, and the amount of failure of potential drugs to make it to market, it’s really a very long ramp up for the few products that actually make it. So, when you think about measuring a value in value-based contracts, it’s probably difficult to actually capture the real value in a 12-month contract, because drugs by meliorating disease, meliorating suffering, tend to have their real value explained over a number of years. Actuarially, while this may become more difficult, I think value-based contracts, if they can be multi-year and over large populations, those are the things we would like to see in the contract.
We’d also like to be able to measure some of the factors that are not traditionally measured, but are very important to patients, such as their quality of life, their outcomes, and what it means for them to be able to care for others, maintain employment, and participate in meaningful activities that they otherwise wouldn’t be able to participate in.
Additionally, I just want to say that as we move into a more aggregated system, where the delivery side has become more group-oriented in ACOs and IDNs, we think that the ability to manage these value-based contracts will become easier because these aggregated delivery systems will be able to present us with that large set of holistic data that I referred to that we will need to actually show the real value of the products in the marketplace for real patients.
Delayed Diagnoses, Oxygen Therapy Use Linked to Worse Outcomes in Patients With Fibrotic ILD
October 21st 2024Posters presented at the CHEST 2024 annual meeting revealed that delays in diagnosing fibrotic interstitial lung disease (ILD) can negatively impact overall survival, while supplemental oxygen therapy may exacerbate clinical burdens through increased rates of acute exacerbations and hospitalizations.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Ways Providers, Payers Can Ensure Biomarker Testing Is Done in Cancer Care
October 18th 2024There is a role for both payers and providers to make small changes that would increase the use of biomarker testing to ensure patients are receiving the appropriate treatment, said Susan Wescott, RPh, MBA, senior director of managed care pharmacy, Mayo Clinic.
Read More
